These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 34955547)

  • 1. Pulmonary Enteric Adenocarcinoma Harboring a BRAF G469V Mutation.
    Shimizu D; Yamamoto H; Shien K; Taniguchi K; Miyoshi K; Namba K; Mesaki K; Sugimoto S; Soh J; Yamane M; Toyooka S
    Acta Med Okayama; 2021 Dec; 75(6):759-762. PubMed ID: 34955547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential diagnosis of pulmonary enteric adenocarcinoma and metastatic colorectal carcinoma with the assistance of next-generation sequencing and immunohistochemistry.
    Zhang J; Xiang C; Han Y; Teng H; Li X; Shao J; Zhu L; Han-Zhang H; Ye J; Yu K
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):269-279. PubMed ID: 30415301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A large-scale, multicenter characterization of BRAF G469V/A-mutant non-small cell lung cancer.
    Wu H; Feng J; Lu S; Huang J
    Cancer Med; 2024 May; 13(10):e7305. PubMed ID: 38770647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. V600E BRAF versus Non-V600E BRAF Mutated Lung Adenocarcinomas: Cytomorphology, Histology, Coexistence of Other Driver Mutations and Patient Characteristics.
    Salimian KJ; Fazeli R; Zheng G; Ettinger D; Maleki Z
    Acta Cytol; 2018; 62(2):79-84. PubMed ID: 29320776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report.
    Reyes R; Mayo-de-Las-Casas C; Teixidó C; Cabrera C; Marín E; Vollmer I; Jares P; Garzón M; Molina-Vila MÁ; Reguart N
    Clin Lung Cancer; 2019 May; 20(3):e219-e223. PubMed ID: 30926357
    [No Abstract]   [Full Text] [Related]  

  • 6. A case of a primary lung cancer comprised of adenocarcinoma and atypical carcinoid tumor with both components harboring BRAF p.V600E mutation.
    Olofson AM; Tafe LJ
    Exp Mol Pathol; 2018 Feb; 104(1):26-28. PubMed ID: 29248665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
    Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG
    Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VPS41-BRAF, a novel BRAF fusion gene identified in a lung adenocarcinoma patient by next-generation sequencing.
    Wang L; Chen A; She X; Xiang J; Tang J
    Lung Cancer; 2020 Aug; 146():380-381. PubMed ID: 32527614
    [No Abstract]   [Full Text] [Related]  

  • 9. Genomic and epigenomic profiles distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancer.
    Zuo Y; Zhong J; Bai H; Xu B; Wang Z; Li W; Chen Y; Jin S; Wang S; Wang X; Wan R; Xu J; Fei K; Han J; Yang Z; Bao H; Shao Y; Ying J; Song Q; Duan J; Wang J
    EBioMedicine; 2022 Aug; 82():104165. PubMed ID: 35901658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung Cancer Driven by BRAF
    Huo KG; Notsuda H; Fang Z; Liu NF; Gebregiworgis T; Li Q; Pham NA; Li M; Liu N; Shepherd FA; Marshall CB; Ikura M; Moghal N; Tsao MS
    J Thorac Oncol; 2022 Feb; 17(2):277-288. PubMed ID: 34648945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.
    Robinson SD; O'Shaughnessy JA; Cowey CL; Konduri K
    Lung Cancer; 2014 Aug; 85(2):326-30. PubMed ID: 24888229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does V600E BRAF mutation predict vinorelbine efficacy? A proof-of-concept from a lung micropapillary adenocarcinoma metastatic to the breast.
    Carassai P; Jocollé G; Donati G; Spinazzé S; Baiocco C; Baderna P; Martinet A; Lococo F; Migliaccio F; Rossi G
    Pathologica; 2017 Dec; 109(4):426-428. PubMed ID: 29449740
    [No Abstract]   [Full Text] [Related]  

  • 13. Microfluidic-Based Immunohistochemistry Combined With Next-Generation Sequencing on Diagnostic Tissue Sections for Detection of Tumoral BRAF V600E Mutation.
    Leblond AL; Rechsteiner M; Jones A; Brajkovic S; Dupouy D; Soltermann A
    Am J Clin Pathol; 2019 Jun; 152(1):59-73. PubMed ID: 31065676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in lung adenocarcinomas: A study from India.
    Singh V; Guleria P; Malik PS; Mohan A; Thulkar S; Pandey RM; Luthra K; Arava S; Ray R; Jain D
    Curr Probl Cancer; 2019 Oct; 43(5):391-401. PubMed ID: 30591192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
    Kinno T; Tsuta K; Shiraishi K; Mizukami T; Suzuki M; Yoshida A; Suzuki K; Asamura H; Furuta K; Kohno T; Kushima R
    Ann Oncol; 2014 Jan; 25(1):138-42. PubMed ID: 24297085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.
    Cremolini C; Di Bartolomeo M; Amatu A; Antoniotti C; Moretto R; Berenato R; Perrone F; Tamborini E; Aprile G; Lonardi S; Sartore-Bianchi A; Fontanini G; Milione M; Lauricella C; Siena S; Falcone A; de Braud F; Loupakis F; Pietrantonio F
    Ann Oncol; 2015 Oct; 26(10):2092-7. PubMed ID: 26153495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological and genetic analyses of pulmonary enteric adenocarcinoma.
    Okada F; Takeda M; Fujii T; Uchiyama T; Sasaki S; Matsuoka M; Nitta Y; Terada C; Maebo K; Morita K; Ishida E; Sawabata N; Ohbayashi C
    J Clin Pathol; 2024 Jan; 77(2):111-115. PubMed ID: 36456172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical detection and categorization of uncommon and concomitant mutations involving BRAF.
    Zheng G; Tseng LH; Chen G; Haley L; Illei P; Gocke CD; Eshleman JR; Lin MT
    BMC Cancer; 2015 Oct; 15():779. PubMed ID: 26498038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous metastasis as a primary presentation of a pulmonary enteric adenocarcinoma.
    Todisco A; Internò V; Stucci LS; Ostuni C; Lovero D; D'Oronzo S; Mele F; Duda L; Palmirotta R; Silvestris F
    Int J Biol Markers; 2019 Dec; 34(4):421-426. PubMed ID: 31556336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct mutational features across preinvasive and invasive subtypes identified through comprehensive profiling of surgically resected lung adenocarcinoma.
    Xiang C; Ji C; Cai Y; Teng H; Wang Y; Zhao R; Shang Z; Guo L; Chen S; Lizaso A; Lin J; Wang H; Li B; Zhang Z; Zhao J; Wei J; Liu J; Zhu L; Fang W; Han Y
    Mod Pathol; 2022 Sep; 35(9):1181-1192. PubMed ID: 35641658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.